Kazia Therapeutics
KZIA
8 hedge funds and large institutions have $328K invested in Kazia Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more capital invested
Capital invested by funds: $279K → $328K (+$48.2K)
14% more funds holding
Funds holding: 7 → 8 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$9.52K |
| 2 |
Morgan Stanley
New York
|
+$6.43K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$4.16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$3.09K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $237K | +$6.43K | +102 | +3% |
|
2
Acadian Asset Management
Boston,
Massachusetts
| $77K | – | – | – |
|
|
3
RhumbLine Advisers
Boston,
Massachusetts
| $8.61K | +$9.52K | +151 | New |
|
|
4
BNP Paribas Financial Markets
Paris,
France
| $3.76K | +$4.16K | +66 | New |
|
|
NA
5
NewEdge Advisors
New Orleans,
Louisiana
| $580 | – | – | – |
|
6
Bank of America
Charlotte,
North Carolina
| $232 | – | – | – |
|
|
AF
7
Allworth Financial
Folsom,
California
| $101 | – | – | – |
|
|
SPIA
8
Steward Partners Investment Advisory
New York
| $29 | – | – | – |
|
|
AF
9
Advisornet Financial
Minnetonka,
Minnesota
| $6 | – | – | – |
|
|
BAM
10
Belpointe Asset Management
Reno,
Nevada
| – | -$3.09K | -60 | Closed |
|
KZIA Hedge Fund Activity: Q2 2023 in Review
8 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q2 2023, worth a combined $328K — up 17% from $279K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new KZIA positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was RhumbLine Advisers, opening a new position worth an estimated $9.52K. The largest seller was Belpointe Asset Management, exiting entirely with an estimated $3.09K sold.
- 8 institutional investors held Kazia Therapeutics (KZIA) as of Q2 2023, up from 7 in Q1 2023.
- Funds reported $328K of Kazia Therapeutics stock for Q2 2023, up 17% quarter-over-quarter.
- 2 funds opened new Kazia Therapeutics positions in Q2 2023 and 1 closed out, a net change of +1 holder.
- The largest Kazia Therapeutics buyer in Q2 2023 was RhumbLine Advisers, an estimated $9.52K added.
- The largest Kazia Therapeutics seller in Q2 2023 was Belpointe Asset Management, an estimated $3.09K sold.
Based on aggregated 13F filings for Q2 2023.